Alloantibodies to factor VIII in haemophilia

Haemophilia

Volumn 17, Issue 4, 2011, Pages 636-640

  Zakarija, A ^a   Harris, S ^a   Rademaker, A W ^a   Brewer, J ^a   Krudysz Amblo, J ^b   Butenas, S ^b   Mann, K G ^b   Green, D ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF VERMONT   (United States)

Author keywords

Alloantibodies; Haemophilia A

Indexed keywords

ALLOANTIBODY; ANTIVIRUS AGENT; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; BODY MASS; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FLUORESCENCE; HEMOPHILIA A; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; MALE; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FACTOR VIII; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HEMOPHILIA A; HIV SEROPOSITIVITY; HUMANS; IMMUNOASSAY; ISOANTIBODIES; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 79959496019     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02468.x     Document Type: Article

References (12)

1. Kasper CK, Aledort LM, Counts RB et al. A more uniform measurement of factor VIII inhibitors. Thromb diath Haemorrh 1975; 34: 869-72.
2. Key NS. Inhibitors in congenital coagulation disorders. Br J Haematol 2004; 127: 379-91.
3. Ling M, Duncan EM, Rodgers SE, Street AM, Lloyd JV. Low detection rate of antibodies to non-functional epitopes on factor VIII in patients with hemophilia A and negative for inhibitors by Bethesda assay. J Thromb Haemost 2003; 1: 2548-53.
4. Krudysz-Amblo J, Parhami-Seren B, Butenas S et al. Quantitation of anti-factor VIII antibodies in human plasma. Blood 2009; 113: 2587-94.
5. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunshoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
6. Biggs R. Human Blood Coagulation, Haemostasis and Thrombosis, 2nd edn. Oxford: Blackwell Scientific Publications, 1976: 684-8.
7. Batlle J, Gomez E, Rendal E et al. Antibodies to factor VIII in plasma of patients with hemophilia A and normal subjects. Ann Hematol 1996; 72: 321-6.
8. Reding MT, Okita DK, Diethelm-Okita BM, Anderson TA, Conti-Fine BM. Epitope repertoire of human CD4+T cells on the A3 domain of coagulation factor VIII. J Thromb Haemost 2004; 2: 1385-94.
9. Bray GL, Kroner BL, Arkin S et al. Loss of high-responder inhibitors in patients with severe hemophilia A and human immunodeficiency virus type 1 infection: a report from the Multi-Center Hemophilia Cohort Study. Am J Hematol 1993; 42: 375-9.
10. Gouw SC, van der Born JG, van den Berg HM, for the CANAL Study group. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109: 4648-54.
11. Santagostino E, Mancuso ME, Rocino A et al. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol 2005; 130: 422-7.
12. Gouw SC, van der Born JG, Auerwwald G, Ettinghausen CE, Tedgard U, van den Berg HM. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007; 13: 149-55.